CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 100 enrolled
Drug / intervention
N-acetylcysteine +1 moredrug
Likely dose
N-acetylcysteine 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01082445
NCT01082445Phase 3Completed
CompareCT.gov

Effects of Prolonged N-acetylcysteine Administration on Foot Ulcer Oxygenation in Diabetic Patients

University of Turin, Italy·interventional·Posted Mar 8, 2010·Updated Mar 8, 2012

In Brief

A Phase 3 clinical trial evaluating N-acetylcysteine and Placebo for Foot Ulcer, Diabetic. Completed, enrolled 100 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether N-acetylcysteine is effective in the treatment or prevention of the foot ulcers in diabetic patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFoot Ulcer, Diabetic
CountriesItaly
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 8, 2010
Enrollment StartAug 1, 2009
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.3 years ago

Interventions

N-acetylcysteinedrug

600 mg, 1 tablet 3 times a day for 3 months

Placebodrug

Placebo